GRAIL Investors Face Final Deadline in Cancer Screening Trial Lawsuit

The lawsuit, filed by Hagens Berman Sobol Shapiro LLP, centers on allegations that GRAIL executives misled shareholders between May 13, 2025, and February 19, 2026. The firm claims leadership promoted the trial’s efficacy while concealing internal data suggesting the study’s three-year follow-up period was insufficient to meet its primary endpoint of reducing late-stage cancer diagnoses.

The facade crumbled on February 19, 2026, when the company admitted the trial failed to reach its primary goal and acknowledged that a longer follow-up period likely should have been implemented. The market reacted violently to the news, as share prices crashed by 50.55% in a single session. The stock dropped from $101.53 to $50.21, wiping out more than $2.2 billion in market value.

Reed Kathrein, the partner leading the investigation, stated the firm is specifically examining when management first realized the trial’s duration was fundamentally flawed. Beyond the class action, the firm is also soliciting whistleblowers with non-public information, noting that such disclosures could be eligible for SEC rewards. Investors seeking to participate as lead plaintiffs must submit their documentation by the close of business today.